No abstract

Um método isocrático de cromatografia líquida de alta resolução de fase reversa (RP-HPLC) foi desenvolvido para determinação de gemifloxacin a granel, em formulações e soro humano a 270 nm. A separação cromatográfica foi adquirida em uma coluna Purospher STAR C 18 (250 × 4,6 mm, 5 µm) usando a fase móvel metanol:água (90:10, v/v) ajustada para pH 2,8 com ácido fosfórico 85% em fluxo de 1,5 mL min -1 a temperatura ambiente. As curvas de calibração mostraram-se lineares dentro do intervalo de 5-100 µg mL -1 com um coeficiente de correlação de 0,9998. Os limites de detecção (LOD) e de quantificação (LOQ) foram 0,015 and 0,045 µg mL -1 , respectivamente. Os resultados de precisão intra-e inter-corridas e de exatidão foram 98,73-100,12%, que foram correlacionados através do teste t student. Este método foi aplicado para interações in vitro do gemifloxacino com elementos essencial e traço.An isocratic reversed phase high-performance liquid chromatographic (RP-HPLC) method has been developed for the determination of gemifloxacin in bulk, dosage formulations and human serum at 270 nm. Chromatographic separation was achieved on Purospher STAR C 18 (250 × 4.6 mm, 5 µm) column using mobile phase methanol:water (90:10, v/v) adjusted pH 2.8 via phosphoric acid 85% having flow rate of 1.5 mL min -1 at ambient temperature. Calibration curves were linear over range of 5-100 µg mL -1 with a correlation coefficient 0.9998. The limit of detection (LOD) and limit of quantitation (LOQ) were 0.015 and 0.045 µg mL -1 , respectively. Intra and inter-run precision and accuracy results were 98.73-100.12% and then correlated through student's t-test. This method was further applied for in vitro interactions of gemifloxacin with essential and trace elements.

A simple reversed phase HPLC method have been successfully developed and validated for the quantitative determination of moxifloxacin (MOX) in bulk material, pharmaceutical formulation and serum. Purospher STAR C18 (25 cm × 4.6 mm, 5 μm) and Discovery C18 (25 cm × 4.6 mm, 5 μm) columns were used. The mobile phase, methanol: acetonitrile: water (85:5:10, v/v/v), pH 2.75 adjusted by phosphoric acid was delivered at a flow rate of 1 mL min−1. The eluents was monitored using UV detector at 290 nm. The proposed method is specific, accurate (99.39‐102.67%), precise (intra‐day variation 0.04‐0.86% and inter‐day variation 0.12‐0.94%) and linearity (R2 > 0.999) within the desired range 0.39‐25 μg mL−1 concentration. The detection and quantification limit was 0.002‐0.51 μg mL−1 and 0.01‐0.555 μg mL−1, respectively. The analysis of variance (ANOVA) and student's t‐test were applied to verify the results. The anticipated method is applicable to routine analysis of MOX in pharmaceutical formulations and human serum samples. It is also applied on interaction of MOX with several essential and trace metals as well as interaction with antacids.

A simple reversed phase HPLC method was developed and validated for the simultaneous determination of sparfloxacin (SPFX), diclofenac sodium, meloxicam, ibuprofen, flurbiprofen, naproxen and mefenemic acid in a relatively short time with high linearity in bulk material, pharmaceutical formulations and human serum. Purospher STAR C 18 (250 × 4.6 mm, 5 μm) column was utilized with mobile phase, methanol and water (90:10, v/v pH 2.70 adjusted by phosphoric acid), was delivered at a flow rate of 1.5 mL·min -1 . Eluent was monitored using UV detector at 240 nm. The proposed method is specific, accurate (98.42% -102.75%), precise (intra-day and inter-day variation 0.011% -1.85%) and linear (R 2 > 0.999) with in the desired range 0.15 -40 µg·mL -1 and the detection and quantification limit was 1.19E+08 -0.150 µg·mL -1 and 3.62E+08 -0.4574 µg·mL -1 respectively for SPFX and NSAIDs. The analysis of variance (ANOVA) and student's t-test were applied to verify the results. The anticipated method is applicable to routine analysis of SPFX and NSAIDs in pharmaceutical formulations as well as in human serum samples. It has also applied on interaction of SPFX with NSAIDs.

No abstract

The convenient synthetic strategy for the one-pot synthesis of silver nanoparticles capped by tartaric acid with a controlled size is reported here. Their characterization is revealed through spectroscopic protocols, such as UV/Vis and FTIR, while SEM, DLS and a Zetasizer revealed the surface morphology, size distribution and surface charge on the nanoparticles. The surface plasmon resonance (SPR) band was observed at 406 nm with 1.07 a.u absorbance, the image for SEM shows that the particles were monodispersed and spherical in shape, while the z-average size distribution of AgNPs/TA in a colloidal solution was found to be 79.20 nm and the surface charge was monitored as −28.2 mV. The antibacterial activities of these capped nanoparticles alone and in synergism with selected fluoroquinolones (ofloxacin, sparfloxacin, ciprofloxacin and gemifloxacin) and macrolides (erythromycin and azithromycin) were assessed on selected Gram-negative as well as Gram-positive organisms by employing the disc diffusion method. Antioxidant activity against the DPPH (1,1-diphenyl-2-picrylhydrazyl) was also evaluated using the standard assay method. The antibacterial activity of the antibiotics has been increased against studied microorganisms, showing the positive synergistic effect of the capped nanoparticles. A potential therapeutic application of AgNPs/TA in combination with antibiotics is determined from the results of the present research. These capped nanoparticles also possess good antioxidant activity and, therefore, can be used in various fields of biomedical sciences.

Background: Gastroesophageal reflux disease (GERD) is a common gastrointestinal disorder that results from regurgitation of acid from the stomach into the esophagus. Treatment available for GERD includes lifestyle changes, antacids, histamine-2 receptor antagonists (H2RAs), proton pump inhibitors (PPIs), and anti-reflux surgery. Aim: The aim of this review is to assess the cost-effectiveness of the use of PPIs in the long-term management of patients with GERD. Method: We searched in PubMed to identify related original articles with close consideration based on inclusion and exclusion criteria to choose the best studies for this narrative review. The first section compares the cost-effectiveness of PPIs with H2RAs in long-term heartburn management. The other sections shall only discuss the cost-effectiveness of PPIs in 5 different strategies, namely, continuous (step-up, step-down, and maintenance), on-demand, and intermittent therapies. Results: Of 55 articles published, 10 studies published from 2000 to 2015 were included. Overall, PPIs are more effective in relieving heartburn in comparison with ranitidine. The use of PPIs in managing heartburn in long-term consumption of nonsteroidal anti-inflammatory drug (NSAID) has higher cost compared with H2RA. However, if the decision-maker is willing to pay more than US$174 788.60 per extra quality-adjusted life year (QALY), then the optimal strategy is traditional NSAID (tNSAID) and PPIs. The probability of being cost-effective was also highest for NSAID and PPI co-therapy users. On-demand PPI treatment strategy showed dominant with an incremental cost-effectiveness ratio of US$2197 per QALY gained and was most effective and cost saving compared with all the other treatments. The average cost-effectiveness ratio was lower for rabeprazole therapy than for ranitidine therapy. Conclusion: Our review revealed that long-term treatment with PPIs is effective but costly. To achieve long-term cost-effective approach, we recommend on-demand approach to treat heartburn symptoms, but if the symptoms persist, treatment with continuous step-down therapy should be applied.

Four new metal complexes (S12-S15) of SPFX (third-generation quinolones) via heavy metals have been synthesized in good yield and characterized by physicochemical and spectroscopic methods including TLC, IR, NMR, and elemental analyses. Sparfloxacinato ligand binds with metals through pyridone and oxygen atom of carboxylic group. The biological actives of complexes have been tested against four Gram-positive and seven Gram-negative bacteria and six different fungi. Statistical analysis of antimicrobial data was done by one-way ANOVA, Dunnett's test; it was observed that S13, S14, and S15 were found to be most active complexes. Antifungal data confirm that all four synthesized complexes are most active and show significant activity against F. solani with respect to parent drug and none of complexes show activity against A. parasiticus, A. effuris, and S. cervicis. To study inhibitory effects of newly formed complexes, enzyme inhibition studies have been conducted against urease,-chymotrypsin, and carbonic anhydrase. Enzymatic activity results of these complexes indicated them to be good inhibitors of urease enzyme while all complexes show mild activities against carbonic anhydrase enzyme. Further research may prove the promising role of these synthesized complexes as urease inhibitors.